Abbott Laboratories (ABT) Non-Current Assets (2009 - 2026)

Abbott Laboratories has disclosed Non-Current Assets across 18 years of filings, most recently posting $84.7 billion for Q2 2026.

• In Q2 2026, Non-Current Assets rose 42.28% year-over-year to $84.7 billion; the TTM figure through Jun 2026 stood at $289.7 billion (up 28.1% YoY), while the FY2025 annual figure was $60.7 billion, up 5.12% from the prior year.
• Non-Current Assets came in at $84.7 billion for Q2 2026 at Abbott Laboratories, roughly flat from $84.9 billion in the prior quarter.
• In the past five years, Non-Current Assets ranged from a high of $84.9 billion in Q1 2026 to a low of $48.0 billion in Q3 2022.
• Average Non-Current Assets over 5 years is $56.2 billion, with a median of $50.5 billion recorded in 2023.
• Year-over-year, Non-Current Assets retreated 4.67% in 2022 and soared 45.67% in 2026.
• Over 5 years, Non-Current Assets stood at $49.2 billion in 2022, then grew by 2.7% to $50.5 billion in 2023, then advanced by 14.27% to $57.8 billion in 2024, then grew by 5.12% to $60.7 billion in 2025, then jumped by 39.5% to $84.7 billion in 2026.
• Per Business Quant data, the three most recent Non-Current Assets figures were $84.7 billion in Q2 2026, $84.9 billion in Q1 2026, and $60.7 billion in Q4 2025.